Continuous showed no clear difference in withdrawal due to adverse events compared with intermittent Antibiotic Infusions (low certainty).
Pregabalin leads to higher withdrawal due to adverse events compared with placebo at end of treatment (high certainty).
Nefopam 60 mg tds showed no clear difference in withdrawal Due to adverse events compared with placebo (moderate certainty).
Oromucosal cannabis (Sativex) showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
It is very uncertain whether muscle relaxant changes withdrawal due to Adverse Events compared with control (very low certainty).
The intervention showed no clear difference in withdrawal due to adverse events (low certainty).
It is very uncertain whether intermittent/cyclic etidronate 400 mg/day changes withdrawals due to adverse events compared with placebo (very low certainty).
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether one‐food elimination diet changes withdrawals due to adverse events compared with six‐food elimination diet (very low certainty).
It is very uncertain whether any cold therapy changes withdrawals due to adverse events compared with no cold therapy following total knee replacement (very low certainty).
It is very uncertain whether any‐treatment‐dose vitamin D (greater than 400 IU/day) changes withdrawals due to adverse events compared with supplemental‐dose vitamin D (less than 400 IU/day) (very low certainty).
It is very uncertain whether vitamin D (all doses) changes withdrawals due to adverse events compared with placebo/no treatment (very low certainty).
It is very uncertain whether high‐treatment‐dose vitamin D (greater than 1000 IU/day) changes withdrawals due to adverse events compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (very low certainty).
Infliximab 5 mg/kg showed no clear difference in withdrawals due to adverse events compared with purine analogues (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Infliximab 5 mg/kg showed no clear difference in withdrawals due to adverse events compared with CT‐P13 biosimilar 5 mg/kg (low certainty).